Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.58 |
| ▸ | HTR3B | O95264 | 3/20 | 0.58 |
| ▸ | HTR3A | P46098 | 3/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23114416 | 0.94 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL18270122 | 0.88 | HTR3A (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4547904 | 0.84 | TRPV3 (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4547896 | 0.84 | TRPV3 (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8274280 | 0.83 | TRPV3 (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL23114437 | 0.82 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8274290 | 0.81 | HTR3A (0.62) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL15341818 | 0.80 | HRH3 (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4547898 | 0.80 | GAA (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL23107095 | 0.78 | ACACB (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| CN-100422181-C | [1,8] naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-101189237-A | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2008-05-28 | — | — | CN | disclosed |
| EP-1869041-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2006-10-19 | — | — | US | disclosed |
| WO-2006103559-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| CN-1839134-A | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2006-09-27 | — | — | CN | disclosed |
| WO-2006090273-A2 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS WITH KETO OR HYDROXYL LINKERS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | HTR3E 411/4885HTR3B 302/4885HTR3A 328/4885 |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | HTR3E 1510/4885HTR3B 1000/4885HTR3A 1159/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HTR3E 1886/4885HTR3B 1473/4885HTR3A 2115/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | HTR3E 1510/4885HTR3B 1000/4885HTR3A 1159/4885 |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | PTGDR, GRIN2A, PTGDR2 | HTR3E 711/4885HTR3B 329/4885HTR3A 164/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | HTR3E 1510/4885HTR3B 1000/4885HTR3A 1159/4885 |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | HTR3E 411/4885HTR3B 302/4885HTR3A 328/4885 |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HTR3E 1886/4885HTR3B 1473/4885HTR3A 2115/4885 |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, IP6K1, PDXK | HTR3E 445/4885HTR3B 370/4885HTR3A 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.